Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of GP40071 Compared to NovoRapid® Penfill® in Type 1 Diabetes Mellitus Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed written consent~* Diabetes mellitus type 1 for at least 12 months prior to screening~* History of basis-bolus (multiple dose injection (MDI)) therapy in stable doses at least 30 days~* Glycated hemoglobin (HbA1c) level of 7.1 to 12.0 % at screening (both values inclusive)~* Body mass index (BMI) of 18.5 to 35 kg/m2 at screening (both values inclusive)~* Subject is able and willing to comply with the requirements of the study protocol~Exclusion Criteria:~* Contraindication to the use of insulin aspart~* Insulin resistance over 1.5 U/kg insulin pro day~* Change INN of insulin for 6 months prior to randomisation~* History of treatment any biosimilar insulin for 6 months prior to randomisation (excl. GEROPHARM's insulins)~* History of treatment any experimental drugs or medical devices for 3 months prior to randomisation~* History of treatment insulin pump for 180 days prior to signed written consent or indication for use insulin pump~* Presence of severe diabetes complications~* History of severe hypoglycemia for 6 months prior to screening~* History of 15 or more episodes mild hypoglycemia for 1 month prior to screening~* History or presence of uncontrolled diabetes mellitus for 6 months prior to screening~* History of administration of glucocorticoids (14 days or more) for 1 year prior to screening~* Administration of any immunosuppressive drugs (Cyclosporine, Methotrexate, Rituximab, etc.)~* History of vaccination for 6 months prior to randomisation~* History of autoimmune disease, except vitiligo and controlled autoimmune polyglandular syndrome (APS) types 1-3, except adrenal insufficiency~* History of unstable angina, myocardial infarction, severe arrhythmia, heart failure III or IV NYHA for 1 year prior to screening~* History of stroke or TIA for 6 months prior to screening~* History of hypersensitivity to any of the active or inactive ingredients of the insulin/insulin analogue preparations used in the trial, OR history of significant allergic drug reactions~* Pregnant and breast-feeding women~* Acute inflammation disease for 3 weeks prior to screening~* Deviation of the laboratory results conducted during the screening:~Hemoglobin value \< 9,0 g/dl; Hematocrit value \< 30 %; ALT and AST value \> 2 folds as high as maximal normal value; Serum bilirubin value \> 1.5 folds as high as maximal normal value~* History of hematological disorders that can affect the reliability of HbA1c estimation (hemoglobinopathies, hemolytic anemia, etc.)~* Serious blood loss for 3 months prior to screening (blood donation, surgery procedure, etc.)~* Incomplete recovery after surgery procedure~* History of drug, alcohol abuse for 3 years prior to screening~* Serological evidence of human immunodeficiency virus (HIV), hepatitis B (HbSAg), hepatitis C (HCVAb) or syphilis (Treponema pallidum) antibodies at screening~* History of oncological disease during 5 years prior to screening~* History of transplantation, except 3 months after corneal transplant~* History or presence of a medical condition or disease that in the investigator's opinion would embarrass glycemic control and completion of the study~* Inability follow to protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- GP40071 (Type: EXPERIMENTAL): Subcutaneous (SC), before meals intake, up to Week 26
- NovoRapid® Penfill® (Type: ACTIVE_COMPARATOR): Subcutaneous (SC), before meals intake, up to Week 26

Based on this trial design, predict the completion outcome and termination type (if applicable).